^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Invasive breast cancer: HER2 negative....Useful in certain circumstances:...Carboplatin + paclitaxel or albumin-bound paclitaxel
Source:
Title:
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Excerpt:
...- The patients must have histologically confirmed breast cancer that is human epidermal growth factor receptor 2 (Her-2) negative (immunohistochemistry [IHC] 0-1+ patients are eligible without fluorescence in situ hybridization [FISH]; IHC2+ patients are eligible with negative FISH; if FISH only is done HER2/chromosome enumeration probe [CEP]17 < 2.0); the invasive tumor must be hormone receptor negative defined as both estrogen receptor and progesterone receptor IHC staining present in less than 10% of invasive cancer cells...
Trial ID:
Source:
Title:
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
Excerpt:
...- HER-2/neu negative (0, 1+, or 2+ by immunohistochemistry or fluorescent in situ hybridization) OR status unknown...
Trial ID:
More C2 evidence
Source:
Title:
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Excerpt:
...Breast cancer must be Human Epidermal Growth Factor Receptor 2 (HER2)-negative....
Trial ID:
Source:
Title:
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Excerpt:
...- At the recommended phase II dose level, triple-negative breast cancer defined as ER-negative, PR-negative, and HER2-negative, will be enrolled and another 10 patients with a solid malignancy who would benefit from a paclitaxel and carboplatin-based regimen, will also be enrolled....
Trial ID:
Source:
Title:
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
Excerpt:
...- HER2-negative (Immunohistochemistry (IHC) score ≤1 or IHC score =2 and negative for the amplification by in situ hybridization);...
Trial ID:
Source:
Title:
Treatment of HER-2 negative breast cancer by neoadjuvant chemotherapy combined with WTPA
Excerpt:
...HER-2 negative confirmed by IHC (negative or 1+) or FISH (negative); 4. ...
Trial ID:
